Par Drugs and Chemicals Limited (NSE:PAR)
90.12
-1.26 (-1.38%)
Jan 23, 2026, 3:29 PM IST
Par Drugs and Chemicals Revenue
Par Drugs and Chemicals had revenue of 286.59M INR in the quarter ending September 30, 2025, a decrease of -17.31%. This brings the company's revenue in the last twelve months to 984.16M, down -5.44% year-over-year. In the fiscal year ending March 31, 2025, Par Drugs and Chemicals had annual revenue of 1.01B with 5.58% growth.
Revenue (ttm)
984.16M
Revenue Growth
-5.44%
P/S Ratio
1.13
Revenue / Employee
8.13M
Employees
121
Market Cap
1.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.01B | 53.33M | 5.58% |
| Mar 31, 2024 | 956.40M | -1.08M | -0.11% |
| Mar 31, 2023 | 957.49M | 206.74M | 27.54% |
| Mar 31, 2022 | 750.74M | 143.23M | 23.58% |
| Mar 31, 2021 | 607.51M | 49.03M | 8.78% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nectar Lifesciences | 16.70B |
| Ind-Swift Laboratories | 5.72B |
| Sigachi Industries | 5.09B |
| Sakar Healthcare | 2.04B |
| Valiant Laboratories | 1.86B |
| Bafna Pharmaceuticals | 1.42B |
| Vaishali Pharma | 1.17B |
| Alpa Laboratories | 1.11B |